Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)

Purpose Randomized trials in aTNBC have demonstrated improved efficacy with addition of Atezo to 1L nab-PAC in patients (pts) with PD-L1+ tumors, and with addition of the AKT inhibitor IPAT to 1L PAC. We report first results from a multicenter phase 1b study (NCT03800836) evaluating a triplet of IPAT, Atezo, and PAC or nab-PAC.